Global Focal Segmental Glomerulosclerosis (FSGS) Market: Overview
This report on focal segmental glomerulosclerosis (FSGS) market studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacturing and commercialization of diagnostic and therapeutic products for focal segmental glomerulosclerosis (FSGS) as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered in the scope of the study. This section also provides the overall information and data analysis of the global focal segmental glomerulosclerosis (FSGS) market with respect to the leading market segments based on disease type, disease management and geographies.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the focal segmental glomerulosclerosis (FSGS) market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global focal segmental glomerulosclerosis (FSGS) market.
Global Focal Segmental Glomerulosclerosis (FSGS) Market: Segmentation
Based on disease type, the focal segmental glomerulosclerosis (FSGS) market has been majorly segmented into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis. In terms of disease management, the focal segmental glomerulosclerosis (FSGS) market has been broadly classified into diagnosis and treatment. Diagnosis includes segments such as kidney biopsy, creatine test, and others. Treatment includes segments such as drug therapy, dialysis, and kidney transplant.
Each of the market segments have been extensively analyzed based on the market related factors such as incidence and prevalence of focal segmental glomerulosclerosis (FSGS), available treatments, and pipeline products. Moreover, historical year-on-year growth have been taken into consideration while estimating the market size. The market size and forecast in terms of US$ million for each segment has been provided for the period from 2015 to 2025. The report also provides the compound annual growth rate (CAGR %) for each market segment for the forecast period from 2017 to 2025, considering 2016 as the base year.
Geographically, focal segmental glomerulosclerosis (FSGS) market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions has been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The report also provides market size and forecast for major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market growth and future opportunities has been provided in the market overview section. This section of the report also provides market attractiveness analysis, porter’s five forces analysis, and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global focal segmental glomerulosclerosis (FSGS) market.
Global Focal Segmental Glomerulosclerosis (FSGS) Market: Competitive Dynamics
The key players operating in the focal segmental glomerulosclerosis (FSGS) market are Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin, Inc., AbbVie, Inc., Novartis AG, Pfizer, Inc., AstraZeneca plc., Sanofi S.A, GlaxoSmithKline plc. and Teva Pharmaceutical Industries Ltd. The global focal segmental glomerulosclerosis (FSGS) market is expected to undergo change after the successful pipeline product launch during the forecast period.
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions
2.2. Research Methodology
3. Executive Summary
3.1. Global Focal Segmental Glomerulosclerosis Market Snapshot
4. Market Overview
4.1. Product Overview
4.2. Key Industry Events
4.3. Global Focal Segmental Glomerulosclerosis Market Size (US$ Mn) Forecast, 2015-2025
4.4. Market Opportunity Map
4.5. Global Focal Segmental Glomerulosclerosis Market Outlook
4.6. Overview of Clinical Trials
4.7. Global Focal Segmental Glomerulosclerosis Prevalence Scenario-2016, by Region
5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.2.1. Increasing burden of focal segmental glomerulosclerosis (FSGS)
5.2.2. Untapped market opportunities with a limited number of pipeline products
5.2.3. Efforts by non-government organizations to raise awareness
5.2.4. Strong focus on R&D activities for developing new therapies and drugs
5.2.5. Rise in funding for research on rare diseases
5.3. Restraints
5.3.1. High cost of kidney dialysis and kidney transplant treatments
5.3.2. Difficulty in recruitment for clinical trials
5.3.3. Non-availability of approved drugs and dearth of trained medical professionals
5.4. Opportunities
5.4.1. Promising pipeline of novel molecules and their approval
5.4.2. Unmet needs for management of focal segmental glomerulosclerosis (FSGS)
6. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
6.1. Introduction
6.2. Key Findings
6.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
6.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
6.4.1. Primary Focal Segmental Glomerulosclerosis
6.4.2. Secondary Focal Segmental Glomerulosclerosis
6.5. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Type
6.6. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Type
6.7. Key Trends
7. Global Focal Segmental Glomerulosclerosis Market Analysis, by Disease Management
7.1. Introduction
7.2. Key Findings
7.3. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
7.4. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
7.4.1. Diagnosis
7.4.2. Treatment
7.5. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
7.5.1. Kidney Biopsy
7.5.2. Creatine Test
7.5.3. Others
7.6. Global Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
7.6.1. Drug Therapy
7.6.2. Dialysis
7.6.3. Kidney Transplant
7.7. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Disease Management
7.8. Key Trends
8. Global Focal Segmental Glomerulosclerosis Market Analysis, by Region
8.1. Global Market Scenario, by Country
8.2. Global Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Region
8.3. Global Focal Segmental Glomerulosclerosis Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
8.4. Global Focal Segmental Glomerulosclerosis Market Attractiveness Analysis, by Region
8.5. Regulatory Scenario by Region/Key Countries
9. North America Focal Segmental Glomerulosclerosis Market Analysis
9.1. Key Findings
9.2. North America Focal Segmental Glomerulosclerosis Market Overview
9.3. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
9.4. North America Focal Segmental Glomerulosclerosis Market Forecast, by Country
9.4.1. U.S.
9.4.2. Canada
9.5. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
9.6. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
9.7. North America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
9.8. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
9.9. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
9.10. North America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
9.11. North America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis
10. Europe Focal Segmental Glomerulosclerosis Market Analysis
10.1. Key Findings
10.2. Europe Focal Segmental Glomerulosclerosis Market Overview
10.3. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
10.4. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Country
10.4.1. Germany
10.4.2. U.K.
10.4.3. Spain
10.4.4. France
10.4.5. Russia
10.4.6. Poland
10.4.7. Rest of Europe
10.5. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
10.6. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
10.7. Europe Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
10.8. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
10.9. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
10.10. Europe Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
10.11. Europe Focal Segmental Glomerulosclerosis Market Attractiveness Analysis
11. Asia Pacific Focal Segmental Glomerulosclerosis Market Analysis
11.1. Key Findings
11.2. Asia Pacific Focal Segmental Glomerulosclerosis Market Overview
11.3. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
11.4. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Country
11.4.1. India
11.4.2. Japan
11.4.3. China
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
11.6. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
11.7. Asia Pacific Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
11.8. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
11.9. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
11.10. Asia Pacific Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
11.11. Asia Pacific Focal Segmental Glomerulosclerosis Market Attractiveness Analysis
12. Latin America Focal Segmental Glomerulosclerosis Market Analysis
12.1. Key Findings
12.2. Latin America Focal Segmental Glomerulosclerosis Market Overview
12.3. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
12.4. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Country
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
12.6. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
12.7. Latin America Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
12.8. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
12.9. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
12.10. Latin America Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
12.11. Latin America Focal Segmental Glomerulosclerosis Market Attractiveness Analysis
13. Middle East & Africa Focal Segmental Glomerulosclerosis Market Analysis
13.1. Key Findings
13.2. Middle East & Africa Focal Segmental Glomerulosclerosis Market Overview
13.3. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Country
13.4. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Country
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Type
13.6. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Type
13.7. Middle East & Africa Focal Segmental Glomerulosclerosis Market Value Share Analysis, by Disease Management
13.8. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management
13.9. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Diagnosis
13.10. Middle East & Africa Focal Segmental Glomerulosclerosis Market Forecast, by Disease Management - Treatment
13.11. Middle East & Africa Focal Segmental Glomerulosclerosis Market Attractiveness Analysis
14. Competition Landscape
14.1. Competition Matrix
14.2. Company Profiles
14.2.1. Variant Pharmaceuticals, Inc.
14.2.1.1. Company Details
14.2.1.2. Business Overview
14.2.1.3. Strategic Overview
14.2.1.4. SWOT Analysis
14.2.2. ChemoCentryx, Inc.
14.2.2.1. Company Details
14.2.2.2. Business Overview
14.2.2.3. Strategic Overview
14.2.2.4. SWOT Analysis
14.2.3. Retrophin, Inc.
14.2.3.1. Company Details
14.2.3.2. Business Overview
14.2.3.3. Strategic Overview
14.2.3.4. SWOT Analysis
14.2.4. AbbVie, Inc.
14.2.4.1. Company Details
14.2.4.2. Business Overview
14.2.4.3. Financial Overview
14.2.4.4. Strategic Overview
14.2.4.5. SWOT Analysis
14.2.5. Novartis AG
14.2.5.1. Company Details
14.2.5.2. Business Overview
14.2.5.3. Financial Overview
14.2.5.4. Strategic Overview
14.2.5.5. SWOT Analysis
14.2.6. Pfizer, Inc.
14.2.6.1. Company Details
14.2.6.2. Business Overview
14.2.6.3. Financial Overview
14.2.6.4. Strategic Overview
14.2.6.5. SWOT Analysis
14.2.7. AstraZeneca plc.
14.2.7.1. Company Details
14.2.7.2. Business Overview
14.2.7.3. Financial Overview
14.2.7.4. Strategic Overview
14.2.7.5. SWOT Analysis
14.2.8. Sanofi S.A.
14.2.8.1. Company Details
14.2.8.2. Business Overview
14.2.8.3. Financial Overview
14.2.8.4. Strategic Overview
14.2.8.5. SWOT Analysis
14.2.9. GlaxoSmithKline plc.
14.2.9.1. Company Details
14.2.9.2. Business Overview
14.2.9.3. Financial Overview
14.2.9.4. Strategic Overview
14.2.9.5. SWOT Analysis
14.2.10. Teva Pharmaceutical Industries Ltd.
14.2.10.1. Company Details
14.2.10.2. Business Overview
14.2.10.3. Financial Overview
14.2.10.4. Strategic Overview
14.2.10.5. SWOT Analysis
